Identifying T-cell receptors (TCRs) that bind tumor-associated antigens (TAAs) with optimal affinity is a key bottleneck in the development of adoptive T-cell therapy of cancer. TAAs are unmutated self proteins, and T cells bearing high-affinity TCRs specific for such antigens are commonly deleted in the thymus. To identify optimal-affinity TCRs, we generated antigen-negative humanized mice with a diverse human TCR repertoire restricted to the human leukocyte antigen (HLA) A*02:01 (ref. 3). These mice were immunized with human TAAs, for which they are not tolerant, allowing induction of CD8⁺ T cells with optimal-affinity TCRs. We isolate TCRs specific for the cancer/testis (CT) antigen MAGE-A1 (ref. 4) and show that two of them have an anti...
The use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered...
(1) Background: Mutation-specific T cell receptor (TCR)-based adoptive T cell therapy represents a t...
A substantial obstacle to the success of adoptive T cell-based cancer immunotherapy is the sub-optim...
Because of tolerance mechanisms, it has been hard to identify the T cell receptors (TCRs) of high-av...
Administration of autologous chimeric antigen receptor engineered T cells to target CD19 on the surf...
Retroviral transfer of T cell antigen receptor (TCR) genes selected by circumventing tolerance to br...
Importance of the field: Adoptive therapy with T cell receptor- (TCR-) redirected T cells has shown ...
To increase the number of cancer patients that can be treated with T cell receptor (TCR) gene therap...
Background NY-ESO-1 is a tumor-specific, highly immunogenic, human germ cell antigen of the MAGE-1 f...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in ...
Abstract Background High-affinity tumor antigen-specific T-cell receptor (TCR) gene is required to e...
The use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered...
e2307, doi:10.3791/2307 (2010). T-cell receptors (TCRs) play a central role in the immune system. TC...
All nucleated cells display a sampling of their protein contents in the form of short 9-10 amino aci...
Chimeric antigen receptor (CAR) T cell therapy has produced impressive clinical results in the treat...
The use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered...
(1) Background: Mutation-specific T cell receptor (TCR)-based adoptive T cell therapy represents a t...
A substantial obstacle to the success of adoptive T cell-based cancer immunotherapy is the sub-optim...
Because of tolerance mechanisms, it has been hard to identify the T cell receptors (TCRs) of high-av...
Administration of autologous chimeric antigen receptor engineered T cells to target CD19 on the surf...
Retroviral transfer of T cell antigen receptor (TCR) genes selected by circumventing tolerance to br...
Importance of the field: Adoptive therapy with T cell receptor- (TCR-) redirected T cells has shown ...
To increase the number of cancer patients that can be treated with T cell receptor (TCR) gene therap...
Background NY-ESO-1 is a tumor-specific, highly immunogenic, human germ cell antigen of the MAGE-1 f...
Adoptive transfer of T cell receptor-engineered (TCR-engineered) T cells is a promising approach in ...
Abstract Background High-affinity tumor antigen-specific T-cell receptor (TCR) gene is required to e...
The use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered...
e2307, doi:10.3791/2307 (2010). T-cell receptors (TCRs) play a central role in the immune system. TC...
All nucleated cells display a sampling of their protein contents in the form of short 9-10 amino aci...
Chimeric antigen receptor (CAR) T cell therapy has produced impressive clinical results in the treat...
The use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered...
(1) Background: Mutation-specific T cell receptor (TCR)-based adoptive T cell therapy represents a t...
A substantial obstacle to the success of adoptive T cell-based cancer immunotherapy is the sub-optim...